BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25260078)

  • 1. [Molecular classification of urogenital cancers].
    Tímár J
    Magy Onkol; 2014 Sep; 58(3):157-60. PubMed ID: 25260078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognostic and predictive molecular markers for urologic cancers].
    Hartmann A; Schlomm T; Bertz S; Heinzelmann J; Hölters S; Simon R; Stoehr R; Junker K
    Urologe A; 2014 Apr; 53(4):491-500. PubMed ID: 24700189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Synchronous triple urogenital cancer (renal cancer, bladder cancer, prostatic cancer): a case report].
    Takada T; Honda M; Momohara C; Komori K; Fujioka H
    Hinyokika Kiyo; 2002 Apr; 48(4):239-42. PubMed ID: 12048939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Family history of urogenital cancers in patients with bladder, renal cell and prostate cancers.
    Randi G; Pelucchi C; Negri E; Talamini R; Galeone C; Franceschi S; La Vecchia C
    Int J Cancer; 2007 Dec; 121(12):2748-52. PubMed ID: 17724720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple urogenital cancer in a patient with a history of heavy smoking who had been exposed to the Hiroshima atomic bomb explosion.
    Hashimoto M; Akaza H; Shibamoto K; Kishi H; Umeda T; Isurugi K; Niijima T; Aso Y
    Jpn J Clin Oncol; 1988 Mar; 18(1):65-8. PubMed ID: 3352142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetics of urological cancers.
    Maher ER
    Br Med Bull; 1994 Jul; 50(3):698-707. PubMed ID: 7987649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
    Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
    Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zinc transporter genes and urological cancers: integrated analysis suggests a role for ZIP11 in bladder cancer.
    Wu L; Chaffee KG; Parker AS; Sicotte H; Petersen GM
    Tumour Biol; 2015 Sep; 36(10):7431-7. PubMed ID: 25900876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitance of urogenital with lymphoid and intestinal malignancies: more than a coincidence.
    Shabtai F; Lask D; Kimchi D; Hart J; Halbrecht I
    Urol Int; 1985; 40(3):145-7. PubMed ID: 4040290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Classical cadherins in urological cancers.
    Giroldi LA; Shimazui T; Schalken JA; Yamasaki H; Bringuier PP
    Morphologie; 2000 Jun; 84(265):31-8. PubMed ID: 11048296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular prognostic markers for urogenital cancers].
    Kubota Y
    Gan To Kagaku Ryoho; 1996 Jul; 23(8):997-1003. PubMed ID: 8687235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Synchronous primary-multiple cancer of the kidney, urinary bladder and prostate gland].
    Vorob'ev AV; Bystrova VV; Kolomoĭtsev SV; Rozova SL
    Vopr Onkol; 1989; 35(10):1256-7. PubMed ID: 2596074
    [No Abstract]   [Full Text] [Related]  

  • 13. [Considerations relating to multiple primary carcinomas of the urinary tract (author's transl)].
    Rovinescu I; Rousseau E
    J Urol Nephrol (Paris); 1976; 82(7-8):621-6. PubMed ID: 1034027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes.
    Saito K; Kihara K
    Int J Urol; 2013 Feb; 20(2):161-71. PubMed ID: 22897628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative promoter methylation analysis of p53 target genes in urogenital cancers.
    Christoph F; Hinz S; Weikert S; Kempkensteffen C; Schostak M; Miller K; Schrader M
    Urol Int; 2008; 80(4):398-404. PubMed ID: 18587251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytologic diagnosis of occult and "in-situ" carcinoma of the urinary system.
    Allegra SR; Fanning JP; Streker JF; Corvese NM
    Acta Cytol; 1966; 10(5):340-9. PubMed ID: 5230228
    [No Abstract]   [Full Text] [Related]  

  • 17. Potential use of RNA interference as therapeutic strategy in urologic cancer.
    Green WJ; James PA; Ratan HL
    Urology; 2011 Sep; 78(3):500-4. PubMed ID: 21741681
    [No Abstract]   [Full Text] [Related]  

  • 18. Genetics in urogenital cancer.
    Lynch HT; Walzak MP
    Urol Clin North Am; 1980 Oct; 7(3):815-29. PubMed ID: 6256928
    [No Abstract]   [Full Text] [Related]  

  • 19. Bibliography. Current world literature. Genitourinary systems.
    Curr Opin Oncol; 2000 May; 12(3):B104-33. PubMed ID: 10841204
    [No Abstract]   [Full Text] [Related]  

  • 20. [Loss of p16 gene in bladder cancer and genitourinary carcinoma cell lines].
    Guo D; Gu F; Zhou A
    Zhonghua Wai Ke Za Zhi; 1996 Nov; 34(11):643-4. PubMed ID: 9590746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.